[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,476,050
  • Shares Outstanding, K 34,143
  • Annual Sales, $ 55,230 K
  • Annual Income, $ -164,080 K
  • EBIT $ -141 M
  • EBITDA $ -140 M
  • 60-Month Beta 1.14
  • Price/Sales 46.08
  • Price/Cash Flow N/A
  • Price/Book 2.79

Options Overview Details

View History
  • Implied Volatility 67.23% (+1.66%)
  • Historical Volatility 34.93%
  • IV Percentile 22%
  • IV Rank 12.91%
  • IV High 164.90% on 12/10/25
  • IV Low 52.76% on 05/15/26
  • Expected Move (DTE 19) 6.72 (9.26%)
  • Put/Call Vol Ratio 0.16
  • Today's Volume 1,913
  • Volume Avg (30-Day) 1,979
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 41,145
  • Open Int (30-Day) 42,477
  • Expected Range 65.81 to 79.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-2.31
  • Number of Estimates 9
  • High Estimate $-1.78
  • Low Estimate $-3.07
  • Prior Year $-1.85
  • Growth Rate Est. (year over year) -24.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
67.11 +8.06%
on 08/03/26
77.22 -6.09%
on 08/13/26
+1.75 (+2.47%)
since 07/28/26
3-Month
54.13 +33.97%
on 06/09/26
77.23 -6.10%
on 07/07/26
+7.51 (+11.55%)
since 05/28/26
52-Week
27.87 +160.21%
on 09/03/25
109.00 -33.47%
on 04/20/26
+43.18 (+147.17%)
since 08/28/25

Most Recent Stories

More News
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO , Aug. 28, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on August 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors...

NKTR : 72.52 (-2.72%)
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

REZOLVE-AD study met all primary and key secondary endpoints, including   EASI-75,   EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w

NKTR : 72.52 (-2.72%)
Nektar: Q2 Earnings Snapshot

Nektar: Q2 Earnings Snapshot

NKTR : 72.52 (-2.72%)
Nektar Therapeutics Announces Second Quarter 2026 Financial Results

SAN FRANCISCO , Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial...

NKTR : 72.52 (-2.72%)
Nektar's Phase Three Timeline Assumes a Regulatory Path That May Not Exist

Barchart Research What to Expect from NKTR Earnings NKTR Generated August 12, 2026 Current Price $76.03 EPS Estimate $$-2.06 Consensus Rating Strong Buy Average Move 3.67% Nektar's Phase Three Timeline...

NKTR : 72.52 (-2.72%)
Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm

NEW YORK , Aug. 11, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ: NKTR) ...

NKTR : 72.52 (-2.72%)
Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , July 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026, after...

NKTR : 72.52 (-2.72%)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO , July 24, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on July 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors...

NKTR : 72.52 (-2.72%)
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Two global registrational Phase 3 trials initiated in ZENITH AD program

NKTR : 72.52 (-2.72%)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO , June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of Nektar's Board of Directors...

NKTR : 72.52 (-2.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration...

See More

Key Turning Points

3rd Resistance Point 78.14
2nd Resistance Point 76.49
1st Resistance Point 74.50
Last Price 72.52
1st Support Level 70.87
2nd Support Level 69.22
3rd Support Level 67.23

See More

52-Week High 109.00
Fibonacci 61.8% 78.01
Last Price 72.52
Fibonacci 50% 68.43
Fibonacci 38.2% 58.86
52-Week Low 27.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.